An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Summary

The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer

Timeline

Start

2008-09

Primary completion

2011-12

Completion

2012-01

Outcome

Outcome not reported

Stopped: “study did not meet pre-specified criteria for continuation following interim futility analysis”

Drugs

Indications